Clinical Trials Browser

Phase 1 × NIH × eribulin × Clear all

NCT06590558 2025-07-03

Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer

Phase 1 Withdrawn

Triple Negative Breast Neoplasms

NCT00410553 2018-10-03

Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by Surgery

Phase 1 Completed

Ovarian Neoplasms

NCT00415324 2014-05-20

Eribulin Mesylate and Cisplatin in Treating Patients With Advanced Solid Tumors

Phase 1 Completed

Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

NCT00047034 2013-01-07

E7389 in Treating Patients With Advanced Solid Tumors

Phase 1 Completed

Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific